Larvol Delta - aTyr-Pharma-Announces-Positive-Data-from-Phase-1b2a-Clinical-Trial-Demonstrating-Consistent-Dose-Response-for-ATYR1923-in-Pulmonary-Sarcoidosis

Stalaris (efzofitimod) - aTyr Pharma, Kyorin

https://www.globenewswire.com/news-release/2021/09/13/2295657/0/en/aTyr-Pharma-Announces-Positive-Data-from-Phase-1b-2a-Clinical-Trial-Demonstrating-Consistent-Dose-Response-for-ATYR1923-in-Pulmonary-Sarcoidosis.html

Sep 13, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next